Myelodysplastic syndrome in an alemtuzumab-treated multiple sclerosis patient

Neurol Sci. 2022 Sep;43(9):5651-5653. doi: 10.1007/s10072-022-06124-6. Epub 2022 May 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alemtuzumab / adverse effects
  • Humans
  • Multiple Sclerosis* / complications
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy
  • Myelodysplastic Syndromes* / complications
  • Myelodysplastic Syndromes* / drug therapy

Substances

  • Alemtuzumab